Non-Alcoholic Fatty Liver Disease Market on Track for Major Expansion by 2032, According to DelveInsight | Pfizer, Eli Lilly and Company, CohBar, Inc., Hoffmann-La Roche, Amgen, Merck Sharp & Dohme LLC, Abbott

DelveInsight's "Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Non-Alcoholic Fatty Liver Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Fatty Liver Disease Market Forecast
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Non-Alcoholic Fatty Liver Disease Market Report:
• The Non-Alcoholic Fatty Liver Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2024, Galectin Therapeutics revealed the results from its global clinical trial, NAVIGATE, which assessed the effectiveness of belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
• In October 2024, PharmaIN Corporation announced that it will present interim results from its ongoing Phase I clinical trial of PHIN-214, its leading candidate, for the prevention and treatment of decompensated cirrhosis.
• The existing pipeline for NASH comprises a wide array of medications. FXR agonists, FGF21 stimulants, FGF19 analogs, glucagon-like peptide-1 (GLP-1) agonists, peroxisome proliferator-activated receptor (PPAR) regulators, THR-β agonists, and several others are among the prominent classes for this condition.
• According to American Liver Foundation (n.d.), NAFLD is the most common chronic liver condition in the United States. It's estimated that about 25% of adults in the U.S. have NAFLD. Of those with NAFLD, about 20% have NASH (5% of adults in the US). Most people with NAFLD have simply fatty live
• According to the study conducted by Foschi et al. (2019), titled, "Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study," the prevalence of non-alcoholic fatty liver disease (NAFLD) was 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) in citizens with than in those without altered liver enzymes
• Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Novo Nordisk A/S, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Madrigal Pharmaceuticals, Altimmune, Inc., GlaxoSmithKline, Axcella Health, Inc, AstraZeneca, Gannex Pharma Co., Ltd., Dexa Medica Group, Boehringer Ingelheim, Can-Fite BioPharma, Rivus Pharmaceuticals, Inc., Regeneron Pharmaceuticals, MediciNova, and others
• Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Semaglutide, Obeticholicacid (OCA), Pegozafermin, DA-1241, NNC0194 0499, J2H-1702, HSK31679, Resmetirom, Pemvidutide, GSK4532990, AXA1125, AZD9550, 2mg of ASC41, Proliverenol, Survodutide, Namodenoson, HU6, ALN-HSD, MN-001, and others
• The Non-Alcoholic Fatty Liver Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Fatty Liver Disease pipeline products will significantly revolutionize the Non-Alcoholic Fatty Liver Disease market dynamics.

Non-Alcoholic Fatty Liver Disease Overview
Non-alcoholic fatty liver disease (NAFLD) is an umbrella term that encompasses the entire spectrum of fatty liver disease, from simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma.

Get a Free sample for the Non-Alcoholic Fatty Liver Disease Market Report -
https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation:
The Non-Alcoholic Fatty Liver Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Non-Alcoholic Fatty Liver Disease
• Prevalent Cases of Non-Alcoholic Fatty Liver Disease by severity
• Gender-specific Prevalence of Non-Alcoholic Fatty Liver Disease
• Diagnosed Cases of Episodic and Chronic Non-Alcoholic Fatty Liver Disease

Download the report to understand which factors are driving Non-Alcoholic Fatty Liver Disease epidemiology trends @ Non-Alcoholic Fatty Liver Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Fatty Liver Disease market or expected to get launched during the study period. The analysis covers Non-Alcoholic Fatty Liver Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Alcoholic Fatty Liver Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Alcoholic Fatty Liver Disease Therapies and Key Companies
• Lanifibranor: Inventiva Pharma
• Tirzepatide: Eli Lilly and Company
• MGL-3196: Madrigal Pharmaceuticals, Inc.
• Obeticholicacid (OCA): Intercept Pharmaceuticals
• Pegozafermin: 89bio, Inc.
• Semaglutide: Novo Nordisk A/S
• DA-1241: NeuroBo Pharmaceuticals Inc
• NNC0194 0499: Novo Nordisk A/S
• J2H-1702: J2H Biotech
• HSK31679: Haisco Pharmaceutical
• Resmetirom: Madrigal Pharmaceuticals
• Pemvidutide: Altimmune, Inc.
• GSK4532990: GlaxoSmithKline
• AXA1125: Axcella Health, Inc
• AZD9550: AstraZeneca
• 2mg of ASC41: Gannex Pharma Co., Ltd.
• Proliverenol: Dexa Medica Group
• Survodutide: Boehringer Ingelheim
• Namodenoson: Can-Fite BioPharma
• HU6: Rivus Pharmaceuticals, Inc.
• ALN-HSD: Regeneron Pharmaceuticals
• MN-001: MediciNova

Discover more about therapies set to grab major Non-Alcoholic Fatty Liver Disease market share @ Non-Alcoholic Fatty Liver Disease Treatment Market
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Market Strengths
• Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed, that will strengthen the market

Non-Alcoholic Fatty Liver Disease Market Opportunities
• Lucrative opportunities for the market growth in United States, owing to presence of large pool of patients suffering from NASH

Scope of the Non-Alcoholic Fatty Liver Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Novo Nordisk A/S, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Madrigal Pharmaceuticals, Altimmune, Inc., GlaxoSmithKline, Axcella Health, Inc, AstraZeneca, Gannex Pharma Co., Ltd., Dexa Medica Group, Boehringer Ingelheim, Can-Fite BioPharma, Rivus Pharmaceuticals, Inc., Regeneron Pharmaceuticals, MediciNova, and others
• Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Semaglutide, Obeticholicacid (OCA), Pegozafermin, DA-1241, NNC0194 0499, J2H-1702, HSK31679, Resmetirom, Pemvidutide, GSK4532990, AXA1125, AZD9550, 2mg of ASC41, Proliverenol, Survodutide, Namodenoson, HU6, ALN-HSD, MN-001, and others
• Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies
• Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Non-Alcoholic Fatty Liver Disease Unmet Needs, KOL's views, Analyst's views, Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement

To know more about Non-Alcoholic Fatty Liver Disease companies working in the treatment market, visit @ Non-Alcoholic Fatty Liver Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Non-Alcoholic Fatty Liver Disease Market Report Introduction
2. Executive Summary for Non-Alcoholic Fatty Liver Disease
3. SWOT analysis of Non-Alcoholic Fatty Liver Disease
4. Non-Alcoholic Fatty Liver Disease Patient Share (%) Overview at a Glance
5. Non-Alcoholic Fatty Liver Disease Market Overview at a Glance
6. Non-Alcoholic Fatty Liver Disease Disease Background and Overview
7. Non-Alcoholic Fatty Liver Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Alcoholic Fatty Liver Disease
9. Non-Alcoholic Fatty Liver Disease Current Treatment and Medical Practices
10. Non-Alcoholic Fatty Liver Disease Unmet Needs
11. Non-Alcoholic Fatty Liver Disease Emerging Therapies
12. Non-Alcoholic Fatty Liver Disease Market Outlook
13. Country-Wise Non-Alcoholic Fatty Liver Disease Market Analysis (2019-2032)
14. Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement of Therapies
15. Non-Alcoholic Fatty Liver Disease Market Drivers
16. Non-Alcoholic Fatty Liver Disease Market Barriers
17. Non-Alcoholic Fatty Liver Disease Appendix
18. Non-Alcoholic Fatty Liver Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Non-Alcoholic Fatty Liver Disease Pipeline https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Alcoholic Fatty Liver Disease market. A detailed picture of the Non-Alcoholic Fatty Liver Disease pipeline landscape is provided, which includes the disease overview and Non-Alcoholic Fatty Liver Disease treatment guidelines.

Non-Alcoholic Fatty Liver Disease Epidemiology https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Alcoholic Fatty Liver Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Alcoholic Fatty Liver Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight:
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.